2023 World Conference on Lung Cancer (Posters)-P1.24. Prognostic Molecular and Genetic Factors in Early Stage Non Small Cell Lung Cancer

P1.24. Prognostic Molecular and Genetic Factors in Early Stage Non Small Cell Lung Cancer - PDF(Slides)

Pdf Summary

This study focused on identifying molecular and genetic factors that can predict the prognosis of patients with early-stage non-small cell lung cancer. The researchers collected demographic, clinical, and pathological data from 78 patients who underwent surgery for stage IA-IIIA lung cancer. Tumor tissue samples were analyzed for various genetic markers including LGALS3, MET, KRAS, NOTCH1, TP53, PIK3CA, NRF2, TRAIL, EGFR, and galectin-3. <br /><br />The results showed that patients without EGFR exon 19 mutations had a lower 5-year survival rate compared to those with type 1 or type 2 mutations. TRAIL mutations, as well as TRAIL-R1 and TRAIL-R2 mutations, did not affect patient survival. However, patients with mutation type 1 or type 2 of TRAIL-C had a higher 5-year survival rate. Galectin-3 mutations were not found to be a prognostic marker.<br /><br />The study concluded that both EGFR and TRAIL-C mutations were independently associated with patient survival and were also related to nodal involvement and tumor stage. These molecular markers could be used as additional prognosticators in early-stage non-small cell lung cancer. The possible use of anti-TRAIL-C agents in the treatment of this type of cancer is yet to be determined.<br /><br />In summary, this study identified specific genetic mutations that can predict the prognosis of patients with early-stage non-small cell lung cancer. Understanding these molecular and genetic factors can help in developing targeted therapies and improving patient outcomes.

Asset Subtitle

Gizem Özçibik Isik

Meta Tag

Speaker Gizem Özçibik Isik

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

molecular factors

genetic factors

prognosis

patients

early-stage non-small cell lung cancer

genetic markers

EGFR exon 19 mutations

5-year survival rate

TRAIL-C mutations

targeted therapies